- Sen. Cory Booker (D-N.J.) is again pushing for easier access to psychedelic drugs, including psilocybin, the active psychedelic compound in "magic mushrooms," and MDMA, for terminally ill patients.
- In July, Booker and Sen. Rand Paul (R-Ky.) introduced legislation to clarify that the Right to Try Act allows for access to some psychedelics and cannabis. Companion legislation was also filed in the House.
- In a video posted to Twitter , Booker said that psilocybin and MDMA particularly "are showing incredible results for helping people with PTSD, with trauma, even with anxiety and depression."
- Several companies are examining psychedelics for mental health disorders, including COMPASS Pathways ( NASDAQ: CMPS ), Cybin ( NYSE: CYBN ), atai Life Sciences ( NASDAQ: ATAI ), and MindMed ( NASDAQ: MNMD ).
- Check out why Seeking Alpha contributor Stephen Tobin is bullish on atai Life Sciences ( ATAI ).
For further details see:
Booker again pushes for easier access to psychedelics for terminally ill patients